Showing results (41-50 of 70) with videos related to

Sort By:
Pageof 7
Frontiers in Oncology|March 29, 2021
Outcomes of Adults With Relapsed/Refractory Acute Myeloid Leukemia Treated With Venetoclax Plus Hypomethylating Agents at a Comprehensive Cancer CenterMatthew E Tenold, Benjamin N Moskoff, David J Benjamin, et al.
Blood|January 4, 2003
Anti-CD22 ligand-blocking antibody HB22.7 has independent lymphomacidal properties and augments the efficacy of 90Y-DOTA-peptide-Lym-1 in lymphoma xenograftsJoseph M Tuscano, Robert T O'Donnell, Laird A Miers, et al.
Cancers|May 1, 2019
A Protective Role of Aryl Hydrocarbon Receptor Repressor in Inflammation and Tumor GrowthChristoph F A Vogel, Yasuhiro Ishihara, Claire E Campbell, et al.
American Journal of Hematology|July 12, 2002
Acetaminophen and diphenhydramine as premedication for platelet transfusions: a prospective randomized double-blind placebo-controlled trialStephen E Wang, Primo N Lara, Angie Lee-Ow, et al.
Cancers|January 28, 2026
Phase I Study of Mogamulizumab in Combination with Pembrolizumab in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma-A National Cancer Institute Experimental Therapeutics Clinical Trials Network (NCI-ETCTN) TrialErel Joffe, Anita Kumar, Joseph M Tuscano, et al.
Leukemia & Lymphoma|February 20, 2016
A phase I pharmacodynamic study of GTI-2040, an antisense oligonucleotide against ribonuclotide reductase, in acute leukemias: a California Cancer Consortium studyMark H Kirschbaum, Paul Frankel, Timothy W Synold, et al.
Oncotarget|December 16, 2014
Metformin and trametinib have synergistic effects on cell viability and tumor growth in NRAS mutant cancerIgor Vujic, Martina Sanlorenzo, Christian Posch, et al.
British Journal of Haematology|July 10, 2013
Single-agent lenalidomide is active in patients with relapsed or refractory aggressive non-Hodgkin lymphoma who received prior stem cell transplantationJulie M Vose, Thomas M Habermann, Myron S Czuczman, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|August 14, 2025
Lymphoma Therapy Response Assessment with Low-Dose [18F]FDG Total-Body PET/CTClemens Mingels, Kevin J Chung, Hande Nalbant, et al.
Molecular Medicine (Cambridge, Mass.)|July 26, 2016
Novel Targeted Therapy for Precursor B Cell Acute Lymphoblastic Leukemia: anti-CD22 Antibody-MXD3 Antisense Oligonucleotide ConjugateNoriko Satake, Connie Duong, Sakiko Yoshida, et al.
Pageof 7